INTRODUCTION {#s1}
============

B-cell neoplasms are clonal expansions of cells and are roughly classified according to the developmental B-cell stage from which the clone arose. The clonal expansion may first be apparent simply as increased white cell counts (lymphocytosis). B-cell development requires stereotypical expression of cell surface receptors, which in turn activate or repress specific signaling pathways and lead to changes in gene expression. The correspondence between the cellular morphology, immunophenotype, and the genotype (inferred by various genetic and cytogenetic assays) can typically be used to diagnose patients and indicate therapeutic options. "Mature" B-cell neoplasms include mantle cell lymphoma (MCL), follicular lymphoma (FL), Burkitt lymphoma (BL), Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphomas (MZLs) and MALT (mucosa-associated lymphoid tissue) lymphomas, chronic lymphocytic leukemia (CLL), and others---each are proposed to correspond to a different normal counterpart ([@PARKERMCS000679C41]), and typically each of them has specific treatment options. In practice, patients may present with a form of disease that defies easy categorization, and thus treatment options are limited.

The use of whole-genome sequencing as an assay to inform clinical decisions is an active area of research. We have established a pipeline capable of providing a clinician-readable report of the affected genes and pathways in individual cancer patients, in a relevant time frame. Ideally, this type of analysis will guide therapeutic options, potentially by repositioning agents already approved for other indications or by resolving the classification of a borderline case. Here, we highlight the utility of a combined analysis that takes into account gene expression data from RNA sequencing (RNA-seq) to assist with the prioritization of variants across the genome for a patient with a lymphocytosis of uncertain etiology.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

A female patient, age 65 yr and with no family history, was found to have a node-negative colorectal tumor. Mismatch repair deficiency (MLH1- and PMS2-low) was identified by immunohistochemistry (IHC), and microsatellite instability was observed. The tumor was resected, and because of the low likelihood of benefit of adjuvant therapy, none was provided. During follow-up 14 mo after the colorectal diagnosis, she was noted to have lymphocytosis of 8.3 × 10^9^/L, comprising mainly small cells, in the absence of any lymphadenopathy or hepatosplenomegaly. Lymphocytosis (4.9 × 10^9^/L) was first documented 18 mo prior to its diagnosis, meaning that its development predated the colorectal diagnosis. Peripheral blood flow cytometry demonstrated a κ-clonal B-cell population that was positive for CD5 and FMC-7-bright, but was negative for CD10, CD23, CD38, CD11c, CD25, and CD103 (Supplemental Fig. S1). The morphology most closely resembled CLL, although the quality of the chromatin was unusual and the cells lacked expression of CD23. Fluorescence in situ hybridization (FISH) for the *IGH-CCND1* t(11;14) rearrangement was negative. FISH for ATM (11q), CEP12 (trisomy 12), D13S319 (13q), and TP53 (17p) were normal. The remainder of the blood counts was normal, and there was no paraproteinemia. A bone marrow biopsy demonstrated involvement of the marrow with small-to-intermediate-sized cells and some plasmacytoid differentiation comprising 60%--70% of marrow cellularity ([Fig. 1](#PARKERMCS000679F1){ref-type="fig"}). No growth centers were identified. Additional immunostaining of the bone marrow biopsy for Cyclin D1 and SOX11 was negative. The patient was diagnosed with a low-grade CD5^+^ B-cell lymphoproliferative disorder with the possibilities including atypical CLL, or a low-grade B-cell lymphoproliferative disorder not otherwise specified, but a CD5^+^ MZL with a leukemic presentation could not be excluded.

![Photomicrographs demonstrating pathological features of the marrow and peripheral blood. (*A*) Bone marrow biopsy shows a clustered, atypical lymphoid infiltrate, with small-to-intermediate-sized cells and some plasmacytoid differentiation. (*B*) Peripheral blood smear shows small amounts of eccentric cytoplasm and confirms mild plasmacytoid differentiation. Scale bar, 50 μm.](ParkerMCS000679_F1){#PARKERMCS000679F1}

Genomic Analyses {#s2b}
----------------

In an attempt to refine the diagnosis and potentially inform the choice of therapeutics, the patient was enrolled in the Personal OncoGenomics (POG) initiative at the British Columbia Cancer Agency. POG aims to identify "actionable" targets of aberrant pathways in a clinically feasible timeline using deep sequencing ([@PARKERMCS000679C21]). After enrollment, a fresh bone marrow sample was flow-sorted for tumor cells using the viable CD19^+^/CD33^−^/CD3^−^ B-cell fraction, with CD19^−^/CD3^+^/CD33^−^ T cells used as the normal sample for germline comparison of variants (Supplemental Fig. S2). Genomic copy number in the B-cell population was inferred by reference to the T-cell population and, consistent with clinical FISH results, indicated a normal karyotype. There was also no evidence for either translocations or significant regions of copy-neutral loss of heterozygosity (LOH) from the genomic data, aside from LOH of the X Chromosome. RNA from the CD19^+^ cells was also isolated and sequenced and expression levels were calculated using RSEM (RNA-Seq by Expectation Maximization; [@PARKERMCS000679C28]; [@PARKERMCS000679C22]).

Expression Analysis {#s2c}
-------------------

The RNA-seq gene expression values from the CD19^+^ B-cell population were compared with a normal B-cell library available at the Genome Sciences Centre. The most differentially expressed genes from this comparison were then compared with previously published microarray data consisting of multiple B-cell disorders (Supplemental Fig. S3; [@PARKERMCS000679C9]). This analysis suggested that the lymphocytosis resembled CLL more than MCL, but splenic marginal zone lymphoma (SMZL) could not be excluded---which is consistent with the final clinical diagnosis. CLL has recently been proposed to be divided into a low-risk, C1 subtype and a higher-risk, C2 subtype using RNA-seq expression analysis ([@PARKERMCS000679C10]). Using the overall expression ranking (of the patient\'s RNA-seq compared with normal B cells) with Gene Set Enrichment Analysis (GSEA) ([@PARKERMCS000679C40]), we found that the gene expression in the patient resembles a C1-subtype CLL (Supplemental Fig. S4). This is consistent with the lack of symptomatic clinical progression or development of cytopenias, with a current observation of 2.5 yr, in this patient.

Variant Analysis {#s2d}
----------------

Variants identified from the whole-genome shotgun sequencing (WGS) by tumor/normal comparisons using paired calls were prioritized based on several filtering steps ([Fig. 2](#PARKERMCS000679F2){ref-type="fig"}; [Table 1](#PARKERMCS000679TB1){ref-type="table"}; details given in the Methods section). Of the expressed genes possessing variants, only three were present in the COSMIC database (Catalogue of Somatic Mutations in Cancer; [@PARKERMCS000679C11]) when filtered for lymphoid origin and population frequency of at least 1%: *APC*, *KLHL6*, and *NOTCH2.* We consider these to be the most relevant variants and discuss each in detail below.

![Overview of the filtering process used to prioritize variants. WGS, whole-genome shotgun sequencing; COSMIC, Catalogue of Somatic Mutations in Cancer; CLL-ES, chronic lymphocytic leukemia---Spain.](ParkerMCS000679_F2){#PARKERMCS000679F2}

###### 

List of genes found to have a somatic mutation in the patient with more than 20 reads supporting the variant and having a predicted moderate or high effect on coding sequence based on the SnpEff algorithm, as well as the predicted functional consequence on the protein as determined by a combination of both SIFT and PolyPhen

  Gene name   Chr   DNA change        Change in representative protein model   Variant type   Alt   Ref   SIFT+ PolyPhen
  ----------- ----- ----------------- ---------------------------------------- -------------- ----- ----- ----------------
  *AGBL4*     1     50163019 A\>G     NP_116174.3:p.Phe83Ser                   SNV            54    63    Damaging
  *AGMO*      7     15405188 C\>T     NP_001004320.1:p.Arg405Glnln             SNV            43    61    Unknown
  *ALOX12*    17    6903771 T\>G      NP_000688.2:p.Asn308Lys                  SNV            35    54    Benign
  *AMZ2*      17    66247254 C\>A     NP_001028741.1:p.Thr174Lys               SNV            27    58    Damaging
  *APC*       5     112173449 A\>G    NP_000029.2:p.Met720Val                  SNV            45    50    Damaging
  *BAG1*      9     33264387 C\>G     NP_004314.5:p.Glu96Gln                   SNV            38    59    Benign
  *CDH19*     18    64211302 A\>G     NP_066976.1:p.Tyr374His                  SNV            44    44    Unknown
  *CDH2*      18    25756984 C\>T     NP_001783.2:p.Met1?                      SL             52    48    Unknown
  *CNN2*      19    1037681 G\>A      NP_004359.1:p.Asp238Asn                  SNV            45    51    Benign
  *CSMD3*     8     113332130 C\>T    NP_443132.3:p.Gly2312Ser                 SNV            48    73    Damaging
  *DAZAP1*    19    1434900 T\>C      NP_061832.2:p.Tyr405His                  SNV            47    54    Damaging
  *EYA1*      8     72184078 C\>T     NP_000494.2:p.Arg294Gln                  SNV            39    67    Unknown
  *FCN1*      9     137804876 C\>T    NP_001994.2:p.Gly152Arg                  SNV            21    59    Damaging
  *KLHL6*     3     183273174 G\>C    NP_569713.2:p.Phe83Leu                   SNV            49    54    Damaging
  *KLHL6*     3     183273195 A\>G    NP_569713.2:p.Leu90Val                   SNV            45    60    Damaging
  *NOTCH2*    1     120458435 T\>TG   NP_077719.2:p.Ile2304HisfsTer9           FS                         
  *OR2B2*     6     27879578 C\>A     NP_149046.2:p.Val174Leu                  SNV            44    42    Benign
  *PDGFRA*    4     55138671 T\>A     NP_006197.1:p.Cys450Ser                  SNV            54    58    Damaging
  *RAPGEF1*   9     134497376 T\>C    NP_941372.1:p.Tyr572Cys                  SNV            45    48    Damaging
  *RRBP1*     20    17639820 C\>T     XP_005260843.1:p.Ala445Thr               SNV            28    330   Benign
  *SAMD12*    8     119593067 G\>T    NP_997389.2:p.Gln27Lys                   SNV            47    63    Damaging
  *SEC14L1*   17    75186921 C\>G     NP_002994.3:p.Pro34Ala                   SNV            38    43    Damaging
  *SLC35A5*   3     112289510 T\>G    NP_060415.1:p.Leu118Arg                  SNV            62    53    Damaging
  *SP4*       7     21521702 C\>T     NP_003103.2:p.Arg690Trp                  SNV            42    67    Damaging
  *TAS2R16*   7     122635631 T\>C    NP_058641.1:p.Thr20Ala                   SNV            65    57    Benign
  *TMED9*     5     177019292 T\>A    NP_059980.2:p.Leu26Gln                   SNV            55    53    Unknown
  *UNC13A*    19    17729273 G\>T     NP_001073890.2:p.Pro1456Gln              SNV            29    45    Damaging
  *VMP1*      17    57816223 TTC\>T   NP_112200.2:p.Leu111PhefsTer40           FS                         

Chr, Chromosome; Alt, coverage at the alternative allele; Ref, coverage of the reference allele; SNV, single-nucleotide variant; SL, translation start site lost; FS, frameshift.

A single-base insertion, expected to cause a frameshift, was detected in the region coding for the PEST domain of NOTCH2 (Supplemental Fig. S5A). Similar mutations have been reported in SMZL and other MZL, as well as at lower frequency in DLBCL. These mutations result in protein stabilization and constitutive activation of NOTCH2 ([@PARKERMCS000679C42]; [@PARKERMCS000679C18]; [@PARKERMCS000679C35]; [@PARKERMCS000679C29]). The presentation of the disease in the case under consideration indicates a more primitive cell type of origin than seen in other B-cell malignancies with NOTCH2-activating mutations, indicating that other, cooperating mutations may be relevant in this case. Although mouse *Notch2* has only been shown to be essential in marginal zone B cells ([@PARKERMCS000679C37]), the transcript is present in earlier B-cell precursors ([@PARKERMCS000679C37]; [@PARKERMCS000679C16]). An activating mutation could thus have a functional consequence in the precursors.

*KLHL6* has previously been reported as a recurrently mutated gene in CLL ([@PARKERMCS000679C30], [@PARKERMCS000679C31]; [@PARKERMCS000679C10]), with an overall prevalence of ∼2% coding mutations in CLL. The two *KLHL6* somatic missense mutations in this patient\'s B cells both occur in the amino-terminal POZ/BTB (Pox virus and zinc finger/bric-a-brac tramtrack broad complex) domain (Supplemental Fig. S5B) and occur in the same allele at approximately the same frequency (Supplemental Table S1). Mutations at these codons are observed at low frequencies (\<0.1%) in the ExAC (Exome Aggregation Consortium) database, and are annotated in dbSNP (Database for Short Genetic Variations), indicating a low-level prevalence in the overall population. *KLHL6* was initially identified as a transcript up-regulated during germinal center B-cell differentiation ([@PARKERMCS000679C14]). Whole-animal and B-cell-specific deletions of the mouse ortholog each show a block in B-cell differentiation between the immature (E) and mature (F) stages ([@PARKERMCS000679C19]). We hypothesize that the two BTB domain mutations in the B-cell compartment of the patient could contribute to a similar differentiation block that is relevant to the disease presentation ([Fig. 3](#PARKERMCS000679F3){ref-type="fig"}).

![Model of the effects of mutated genes in this patient. We hypothesize that a partial block in normal B-cell development occurred in this patient because of the *KLHL6* mutation, and combined with activation of the cooperating pathways Notch and β-catenin, led to proliferation of a transitional cell type expressing a mix of classic B-cell surface markers.](ParkerMCS000679_F3){#PARKERMCS000679F3}

The final gene of interest present in primary lymphoid samples in COSMIC is *APC*. The APC protein is a well-known tumor suppressor in colorectal cancer but is not believed to be relevant in lymphoid neoplasms ([@PARKERMCS000679C39]). *APC* is expressed, albeit at low levels, in the patient\'s B cells, the CLL-ES cohort, and in all mouse B-cell populations examined (Supplemental Table S1). The predicted somatic missense mutation lies in the carboxy-terminal armadillo repeat (Supplemental Fig. S5C). This position is not found to be altered in ExAC, and the mutant allele is expressed in the tumor (Supplemental Table S1). One of the other genes having somatic mutations in this patient, but at a lower frequency in lymphoid samples in COSMIC, is *RAPGEF1*, which, like *APC*, encodes a negative regulator of β-catenin ([@PARKERMCS000679C7]). The mutation in *RAPGEF1*, Y572C, occurs at the same position as COSMIC mutation 1901064 (which is Y572H). β-catenin pathway--activating mutations have been previously reported in CLL ([@PARKERMCS000679C43]), and thus we hypothesize that reduced activity of APC or RAPGEF1, or both, may contribute to the proliferation of the mutant clone ([Fig. 3](#PARKERMCS000679F3){ref-type="fig"}).

The other genes implicated in this patient that are present below 1% in COSMIC are *AMZ2*, *DAZAP1*, *FCN1*, *SEC14L1*, *SLC35A5*, *SP4*, *TMED9*, and *VMP1*. The predicted nonsense mutation in the *VMP1* gene would result in a truncated protein very likely to be unstable, likely resulting in haplodeficiency of the gene product. VMP1 is an integral membrane protein that recruits the adaptor protein Beclin 1 in an early stage of autophagy ([@PARKERMCS000679C34]; [@PARKERMCS000679C27]), suggesting that autophagy-dependent cell death may be reduced in the malignant clone.

Splicing factors, specifically SF3B1, have been previously implicated in CLL ([@PARKERMCS000679C32]; [@PARKERMCS000679C17]), and the *DAZAP1* gene product has been implicated in splicing regulation ([@PARKERMCS000679C4]). The missense mutation in DAZAP1 is in its carboxy-terminal domain, which has been shown to mediate interactions with, and antagonize the splicing-inhibitory functions of, hnRNP A1 proteins ([@PARKERMCS000679C4]). This implies that the *DAZAP1* variant could have functional consequences via unknown downstream splicing effects.

Of the remaining candidate genes (*AMZ2*, *FCN1*, *SEC14L1*, *SLC35A5*, *SP4*, and *TMED9*), less is known, especially in cells of lymphoid origin, but all are expressed and predicted to have damaging missense mutations in this patient\'s B-cell clone. As with *DAZAP1*, any or all could have pleiotropic effects. AMZ2 is a protease ([@PARKERMCS000679C44]), although the observed mutation (T174K) does not fall within the predicted peptidase domain. *FCN1* is known to be highly polymorphic and encodes Ficolin 1, a soluble pattern-recognition molecule and activator of the complement system ([@PARKERMCS000679C10]). *SEC14L1* is a putative biomarker for aggressive prostate cancers ([@PARKERMCS000679C1]; [@PARKERMCS000679C2]) and was independently identified as a binding partner and negative regulator of the RIG-I protein (encoded by *DDX58*), which stimulates IFN (interferon)-β after binding single-stranded RNA viruses ([@PARKERMCS000679C25]). The observed mutation in SEC14L1 occurs in the amino terminal of the PRELI-MSF1 domain and results in a proline-to-alanine missense mutation that may disrupt folding of the domain by altering a loop between two β helices ([@PARKERMCS000679C26]). SLC35A5 is a solute carrier of unknown endogenous function, and the observed missense variant occurs in the nucleotide-sugar transporter domain. SP4 is a transcription factor best characterized in neurons and cardiac cells but which has paralogs implicated in cancers ([@PARKERMCS000679C36]), and TMED9 is a Golgi-associated protein, but the observed variant does not fall within annotated domains in either of these proteins.

Finally, as the patient\'s lymphoproliferative disorder was concurrent with a sporadic colorectal tumor, we verified that there were no germline nonsynonymous variants in genes relevant to hereditary nonpolyposis colorectal cancers (data not shown).

Integrative Analysis {#s2e}
--------------------

RNA expression profiling can also be used to find evidence that supports the purely variant-based hypotheses above or to find new observations that may be worth further investigation. For example, consistent with the expectation of NOTCH2 activation due to its predicted truncating mutation, the known NOTCH2 target gene *DTX1* is overexpressed relative to normal B cells. The transcription factor KLF2 has emerged as another important player in SMZL, and loss-of-function mutations in this gene are proposed to contribute to the homing of B cells to the marginal zone ([@PARKERMCS000679C6]). Consistent with this model, in this patient, in whom the marginal zone is not involved, *KLF2* is one of the most up-regulated genes (Supplemental Table S2).

Inspection of the most overexpressed genes as compared with normal B cells (Supplemental Table S2) also led us to observe that one molecule that is up-regulated in the patient, perhaps as a consequence of activation of the β-catenin pathway ([@PARKERMCS000679C20]), is the embryonic transcription factor Brachyury. This gene, which is not normally expressed during B-cell development ([@PARKERMCS000679C16]), is also expressed at very low levels in all samples in the CLL-ES RNA-seq data (Supplemental Fig. S6). The actual cause, or potential consequences, of Brachyury expression in B cells remains an open question for further research. Aberrant expression of Brachyury in some solid tumors contributes to epithelial-to-mesenchymal transformation, but its expression in lymphoid cells has not previously been reported.

DISCUSSION {#s3}
==========

The genomic analysis presented here highlights the utility of expression data as an adjunct to prioritizing variants of interest. Even in the absence of directly comparable samples, gene expression profiles from both the biopsy and literature provided useful information. By aggregating expression profiles, we performed a simple version of sample-based expression clustering, which indicates the patient\'s B cells resemble a low-grade CLL. This is at odds with both the mutation profile, which is overall most consistent with DLBCL, and the presence of the *NOTCH2* mutation, which is most strongly associated with SMZL. It is possible that this type of indolent lymphoproliferative disorder often goes undiagnosed, as it may have been in this case if it were not found secondary to the colorectal cancer. Another strong possibility is that similar cases with unclear diagnoses may be excluded from most current large-scale analyses.

Together, the observations outlined in this paper lead us to a speculative model ([Fig. 3](#PARKERMCS000679F3){ref-type="fig"}) in which a combination of proliferative signals and differentiation blocks leads to the expansion of a postgerminal center B-cell type. Of the 12 genes that we identified as having somatic variants that are expressed, only two of those genes, *NOTCH2* and *KLHL6*, have well-established roles in B cells. Several of the other genes of interest, including *RAPGEF1*, *APC*, and *VMP1*, have variants or known associations with B-cell neoplasms that make them interesting candidates for further study. However, the full implications for this patient and her treatment remain unclear. Should she require chemotherapy in the future, the mutations identified herein may be informative. For now, the findings that there are no mutations indicative of aggressive disease, and that the gene expression is consistent with a low-grade disease, are positive for the patient.

METHODS {#s4}
=======

FISH assays and IHC were performed by the clinical laboratories at the BC Cancer Agency according to established protocols. Two hundred nuclei were examined per FISH assay. Library construction was performed using standard protocols, and sequencing was performed using Illumina sequencers as indicated. One microgram of DNA from CD19^+^ cells was used as input to a PCR (polymerase chain reaction)-free WGS protocol and sequenced on a HiSeq 2000 to 106× coverage; control (CD3^+^ fraction) was similarly sequenced to 45× coverage. Additionally 4 µg of total RNA (RIN 8.0) was subjected to poly(A) selection followed by ssRNA-seq on a HiSeq 2000 instrument to a total of 370 million reads. Reads were aligned to the human genome (GRCh37-lite) using BWA (0.5.7) ([@PARKERMCS000679C24]). Reads from multiple lanes were merged and duplicate marked using Picard (v1.38, <https://github.com/broadinstitute/picard>). Variants were called using mpileup (SAMtools v0.1.17) ([@PARKERMCS000679C23]) and subsequently filtered with varFilter. The tumor sample was compared with the normal sample to identify somatic copy-number variants (CNAseq v0.0.6, <http://www.bcgsc.ca/platform/bioinfo/software/cnaseq>), LOH events (APOLLOH v0.1.1, using the "K18 params Illumina stromalRatio Hyper10k min10max200" parameter matrix, downloaded from <http://compbio.bccrc.ca/software/apolloh/>) ([@PARKERMCS000679C15]), single-nucleotide variants (SAMtools v0.1.17, MutationSeq v1.0.2 \[[@PARKERMCS000679C8]\], Strelka v0.4.6.2 \[[@PARKERMCS000679C38]\]), and small insertions and deletions (Strelka v0.4.6.2). RNA-seq reads were analyzed with JAGuaR (Junction Alignments to Genome for RNA-Seq Reads; [@PARKERMCS000679C3]) to include alignments to a database of exon junction sequences and subsequent repositioning onto the genomic reference. RNA-seq data were processed using the Genome Sciences Centre (GSC)'s WTSS (whole-transcriptome shotgun sequencing) pipeline coverage analysis (v1.1) using the "stranded" option to determine gene and exon read counts and normalized expression level. Expressed variants were called with SNVMix2 (v0.12.1-rc1) ([@PARKERMCS000679C13]) and SAMtools (v0.1.17). Gene expression in the tumor was compared with a compendium of normal tissues and to one or more normal libraries from the same tissue type to identify up- or down-regulated genes. Both genomic and RNA-seq tumor data were also assembled using Trans-ABySS (v1.4.3) ([@PARKERMCS000679C33]) to identify structural variants and fusion genes. Variants were annotated to genes using the Ensembl database (v59,69).

Expression profiling analysis was carried out with pairwise comparisons of the CD19^+^ fraction of the patient\'s bone marrow relative to a normal B-cell library, against CD19^+^ populations from 17 CLL patient samples, 15 conventional MCLs, seven indolent MCLs, and four SMZLs (NCBI \[National Center for Biotechnology Information\] GEO \[Gene Expression Omnibus\] data set GSE16455 \[[@PARKERMCS000679C9]\]). For these, we carried out pairwise comparisons between each group and the CLL samples by extracting lists of the 150 genes most significantly over- or underexpressed relative to CLLs. We then determined the extent to which genes in these lists were expressed in the patient\'s transcriptome relative to a control B-cell library.

Recurrent mutations were identified from COSMIC complete mutation data (CosmicCompleteExportIncFus_v68_210114) parsed by tissue to include only samples of lymphoid origin using the provided web tools. The CLL-ES RNA-seq data set of 109 samples was obtained from International Cancer Genome Consortium (ICGC) DCC version 16 (<https://dcc.icgc.org/projects/CLLE-ES>). In a publication describing the analysis of RNA-seq data from an overlapping cohort ([@PARKERMCS000679C10]), 98 RNA-seq samples (41 IgVH \[immunoglobulin heavy chain variable\]-normal and 54 IgVH-mutated \<98% identity) are described.

Twenty-seven genes, containing 28 coding somatic single-nucleotide variants (SNVs), were identified as having more than 20 reads representing the alternate allele and predicted to have altered amino acid sequence by SnpEff ([Table 1](#PARKERMCS000679TB1){ref-type="table"}; [@PARKERMCS000679C5]). The SIFT ([@PARKERMCS000679C11]) and PolyPhen-2 ([@PARKERMCS000679C10]) algorithms were then applied in tandem, and variants were filtered out if both algorithms provided a benign/nondamaging interpretation. The remaining 21 genes were then examined for expression in the CD19^+^ tumor cells; genes not expressed were also checked for expression in alternative data sources (CLL RNA-seq data from the ICGC \[[@PARKERMCS000679C10]\], and the ImmGen mouse developmental B-cell resource \[[@PARKERMCS000679C16]\]) to check whether those genes are expected to be expressed in B cells. None of the 21 genes was found to be expressed in these data sets.
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